Video

'Out of the Blue' Diagnosis Linked to a Family History of Cancer Now Empowers Others

Author(s):

SUE FRIEDMAN, DVM
Conference|ASCO Annual Meeting

Sue Friedman, founder and executive director of FORCE, discussed how a breast cancer diagnosis at age 33 and a family history of cancer led to the creation of Facing Our Risk of Cancer Empowered.

A breast cancer diagnosis at the age of 33 that felt like it was “out of the blue” led to the creation of Facing Our Risk of Cancer Empowered (FORCE).

Founder and executive director Sue Friedman was inspired to found the organization following her own cancer diagnosis and eventual linkage to family history with cancer. It wasn’t until 1996, “the early days of genetic testing,” that Friedman read an article about hereditary cancers and genetic testing. She then began to understand some of the factors that put her at risk.

At the 2019 American Society of Clinical Oncology Annual Meeting, Friedman discussed her journey and why she immediately began FORCE following the conclusion of her treatment. “I didn’t think anyone should have to face this challenge alone,” she said.

Related Videos
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Image of woman with dark hair, smiling.
Related Content
"FDA" text.
January 17th 2025

FDA Approves Datroway for HR+, HER2- Breast Cancer

Alex Biese
Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of pills that spell "side FX"
January 15th 2025

Elinzanetant May Treat Hot Flashes Caused by Breast Cancer Treatment

Spencer Feldman
Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Illustration of woman with grey hair.
January 9th 2025

A New Year, A New Approach to Survivorship After Cancer

Felicia Mitchell
As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and my hopes for the future.
An image of a doctor and patient talking with one another.
January 9th 2025

Minoxidil May Safely Aid in Hair Growth for Patients With Breast Cancer

Alex Biese
Low-dose oral minoxidil, the hair growth drug that is the active ingredient in Rogaine, may be safe and effective for patients with breast cancer.